Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Studied

Double-blind phase 2 trial comparing weekly LY3298176, now known as tirzepatide, at four doses with dulaglutide or placebo.

Who / model

The study randomized 318 adults with inadequately controlled type 2 diabetes; 316 received treatment, and 258 completed 26 weeks of treatment.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

HbA1c reductions were dose-dependent, reaching -1·94% with 15 mg versus -0·06% with placebo and -1·21% with dulaglutide. Weight change ranged from -0·9 kg to -11·3 kg. Gastrointestinal events increased with dose; no severe hypoglycaemia was reported.

Limits

This 26-week phase 2 trial had incomplete treatment completion and was funded by Eli Lilly. It does not establish longer-term effectiveness or safety.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary